nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

19.07.2019 | Review

Epidemiology, pathogenetic mechanism, clinical characteristics, and treatment of Vibrio vulnificus infection: a case report and literature review

verfasst von: Fei Leng, Shilong Lin, Wei Wu, Jincheng Zhang, Jieqiong Song, Ming Zhong

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Vibrio vulnificus is a Gram-negative bacterium that belongs to the Vibrionaceae family. It represents a deadly opportunistic human pathogen which grows in water with the proper temperature and salinity, and is mostly acquired from seafood eating or direct contact. In susceptible individuals, a traumatic infection could be fatal, causing severe wound infection and even septic shock, and may require amputation. Global warming plays an important role in the geographical area expanding of Vibrio disease. The pathogenesis of Vibrio vulnificus–associated sepsis is very complex, including iron intake, cell injury, and adhesion-related protein and virulence regulation. Vibrio vulnificus infection mainly manifests clinical subtypes such as primary sepsis, traumatic infection, and gastroenteritis, with rapid symptom progression and signs of multiple organ dysfunction syndrome (MODS). It is important to assess these pathogenetic mechanisms in order to select more appropriate measures to prevent and treat Vibrio vulnificus infections, including antibiotic usage and surgical intervention. In this work, we report a typical case of successful treatment of necrotizing fasciitis caused by Vibrio vulnificus, and review the epidemiology, pathogenetic mechanism, clinical characteristics, and treatment of Vibrio vulnificus infection.

Roland FP (1970) Leg gangrene and endotoxin shock due to vibrio parahaemolyticus--an infection acquired in New England coastal waters. N Engl J Med 282(23):1306. https://doi.org/10.1056/nejm197006042822306 CrossRefPubMed

Yun NR, Kim DM, Lee J, Han MA (2015) pH level as a marker for predicting death among patients with Vibrio vulnificus infection, South Korea, 2000-2011. Emerg Infect Dis 21(2):259–264. https://doi.org/10.3201/eid2102.131249 CrossRefPubMedPubMedCentral

Williams TC, Froelich BA, Phippen B, Fowler P, Noble RT, Oliver JD (2017) Different abundance and correlational patterns exist between total and presumed pathogenic Vibrio vulnificus and V. parahaemolyticus in shellfish and waters along the North Carolina coast. FEMS Microbiol Ecol 93(6). https://doi.org/10.1093/femsec/fix071

Huang KC, Weng HH, Yang TY, Chang TS, Huang TW, Lee MS (2016) Distribution of fatal Vibrio vulnificus necrotizing skin and soft-tissue infections: a systematic review and meta-analysis. Medicine 95(5):e2627. https://doi.org/10.1097/md.0000000000002627 CrossRefPubMedPubMedCentral

Oishi H, Ura Y, Mitsumizo S, Nakashima M (2006) A collective review of Vibrio vulnificus infection in Japan. Kansenshogaku Zasshi 80(6):680–689CrossRef

Hsueh PR, Lin CY, Tang HJ, Lee HC, Liu JW, Liu YC, Chuang YC (2004) Vibrio vulnificus in Taiwan. Emerg Infect Dis 10(8):1363–1368. https://doi.org/10.3201/eid1008.040047 CrossRefPubMedPubMedCentral

Baker-Austin C, Trinanes JA, Taylor NGH, Hartnell R, Siitonen A, Martinez-Urtaza J (2012) Emerging Vibrio risk at high latitudes in response to ocean warming. Nat Clim Chang 3(1):73–77. https://doi.org/10.1038/nclimate1628 CrossRef

Levy S (2015) Warming trend: how climate shapes Vibrio ecology. Environ Health Perspect 123(4):A82–A89. https://doi.org/10.1289/ehp.123-A82 CrossRefPubMedPubMedCentral

Johnson CN, Flowers AR, Noriea NF 3rd, Zimmerman AM, Bowers JC, DePaola A, Grimes DJ (2010) Relationships between environmental factors and pathogenic Vibrios in the northern Gulf of Mexico. Appl Environ Microbiol 76(21):7076–7084. https://doi.org/10.1128/aem.00697-10 CrossRefPubMedPubMedCentral

10.

Igbinosa EO, Obi CL, Okoh AI (2011) Seasonal abundance and distribution of Vibrio species in the treated effluent of wastewater treatment facilities in suburban and urban communities of Eastern Cape Province, South Africa. J Microbiol (Seoul, Korea) 49(2):224–232. https://doi.org/10.1007/s12275-011-0227-x CrossRef

11.

Singleton FL, Attwell R, Jangi S, Colwell RR (1982) Effects of temperature and salinity on Vibrio cholerae growth. Appl Environ Microbiol 44(5):1047–1058PubMedPubMedCentral

12.

Sobrinho Pde S, Destro MT, Franco BD, Landgraf M (2014) A quantitative risk assessment model for Vibrio parahaemolyticus in raw oysters in Sao Paulo State, Brazil. Int J Food Microbiol 180:69–77. https://doi.org/10.1016/j.ijfoodmicro.2014.04.008 CrossRefPubMed

13.

Johnson CN, Bowers JC, Griffitt KJ, Molina V, Clostio RW, Pei S, Laws E, Paranjpye RN, Strom MS, Chen A, Hasan NA, Huq A, Noriea NF 3rd, Grimes DJ, Colwell RR (2012) Ecology of Vibrio parahaemolyticus and Vibrio vulnificus in the coastal and estuarine waters of Louisiana, Maryland, Mississippi, and Washington (United States). Appl Environ Microbiol 78(20):7249–7257. https://doi.org/10.1128/aem.01296-12 CrossRefPubMedPubMedCentral

14.

Macian MC, Arias CR, Aznar R, Garay E, Pujalte MJ (2000) Identification of Vibrio spp. (other than V. vulnificus) recovered on CPC agar from marine natural samples. Int Microbiol 3(1):51–53PubMed

15.

Froelich BA, Williams TC, Noble RT, Oliver JD (2012) Apparent loss of Vibrio vulnificus from North Carolina oysters coincides with a drought-induced increase in salinity. Appl Environ Microbiol 78(11):3885–3889. https://doi.org/10.1128/aem.07855-11 CrossRefPubMedPubMedCentral

16.

Paz S, Bisharat N, Paz E, Kidar O, Cohen D (2007) Climate change and the emergence of Vibrio vulnificus disease in Israel. Environ Res 103(3):390–396. https://doi.org/10.1016/j.envres.2006.07.002 CrossRefPubMed

17.

Bisharat N, Agmon V, Finkelstein R, Raz R, Ben-Dror G, Lerner L, Soboh S, Colodner R, Cameron DN, Wykstra DL, Swerdlow DL, Farmer JJ 3rd (1999) Clinical, epidemiological, and microbiological features of Vibrio vulnificus biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel. Israel Vibrio Study Group Lancet (London, England) 354(9188):1421–1424CrossRef

18.

Bisharat N, Raz R (1996) Vibrio infection in Israel due to changes in fish marketing. Lancet (London, England) 348(9041):1585–1586. https://doi.org/10.1016/s0140-6736(05)66199-5 CrossRef

19.

Kim DM, Jung SI, Jang HC, Lee CS, Lee SH, Yun NR, Neupane GP, Park KH (2011) Vibrio vulnificus DNA load and mortality. J Clin Microbiol 49(1):413–415. https://doi.org/10.1128/jcm.01913-09 CrossRefPubMed

20.

Motes ML, DePaola A, Cook DW, Veazey JE, Hunsucker JC, Garthright WE, Blodgett RJ, Chirtel SJ (1998) Influence of water temperature and salinity on Vibrio vulnificus in Northern Gulf and Atlantic Coast oysters (Crassostrea virginica). Appl Environ Microbiol 64(4):1459–1465PubMedPubMedCentral

21.

Watanabe H, Miyoshi S, Kawase T, Tomochika K, Shinoda S (2004) High growing ability of Vibrio vulnificus biotype 1 is essential for production of a toxic metalloprotease causing systemic diseases in humans. Microb Pathog 36(3):117–123CrossRef

22.

Kaspar CW, Tamplin ML (1993) Effects of temperature and salinity on the survival of Vibrio vulnificus in seawater and shellfish. Appl Environ Microbiol 59(8):2425–2429PubMedPubMedCentral

23.

Miyoshi N, Shimizu C, Miyoshi S, Shinoda S (1987) Purification and characterization of Vibrio vulnificus protease. Microbiol Immunol 31(1):13–25CrossRef

24.

Shinoda S, Miyoshi S (2011) Proteases produced by vibrios. Biocontrol Sci 16(1):1–11CrossRef

25.

Natividad-Bonifacio I, Fernandez FJ, Quinones-Ramirez EI, Curiel-Quesada E, Vazquez-Salinas C (2013) Presence of virulence markers in environmental Vibrio vulnificus strains. J Appl Microbiol 114(5):1539–1546. https://doi.org/10.1111/jam.12149 CrossRefPubMed

26.

Elgaml A, Higaki K, Miyoshi S (2014) Effects of temperature, growth phase and luxO-disruption on regulation systems of toxin production in Vibrio vulnificus strain L-180, a human clinical isolate. World J Microbiol Biotechnol 30(2):681–691. https://doi.org/10.1007/s11274-013-1501-3 CrossRefPubMed

27.

Shapiro RL, Altekruse S, Hutwagner L, Bishop R, Hammond R, Wilson S, Ray B, Thompson S, Tauxe RV, Griffin PM (1998) The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988-1996. Vibrio Working Group. J Infect Dis 178(3):752–759CrossRef

28.

Inoue Y, Ono T, Matsui T, Miyasaka J, Kinoshita Y, Ihn H (2008) Epidemiological survey of Vibrio vulnificus infection in Japan between 1999 and 2003. J Dermatol 35(3):129–139. https://doi.org/10.1111/j.1346-8138.2008.00432.x CrossRefPubMed

29.

Pajuelo D, Hernandez-Cabanyero C, Sanjuan E, Lee CT, Silva-Hernandez FX, Hor LI, MacKenzie S, Amaro C (2016) Iron and Fur in the life cycle of the zoonotic pathogen Vibrio vulnificus. Environ Microbiol 18(11):4005–4022. https://doi.org/10.1111/1462-2920.13424 CrossRefPubMed

30.

Stefanova D, Raychev A, Arezes J, Ruchala P, Gabayan V, Skurnik M, Dillon BJ, Horwitz MA, Ganz T, Bulut Y, Nemeth E (2017) Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. Blood 130(3):245–257. https://doi.org/10.1182/blood-2017-03-772715 CrossRefPubMedPubMedCentral

31.

Thiaville PC, Bourdage KL, Wright AC, Farrell-Evans M, Garvan CW, Gulig PA (2011) Genotype is correlated with but does not predict virulence of Vibrio vulnificus biotype 1 in subcutaneously inoculated, iron dextran-treated mice. Infect Immun 79(3):1194–1207. https://doi.org/10.1128/iai.01031-10 CrossRefPubMedPubMedCentral

32.

Lee SJ, Jung YH, Oh SY, Song EJ, Choi SH, Han HJ (2015) Vibrio vulnificus VvhA induces NF-kappaB-dependent mitochondrial cell death via lipid raft-mediated ROS production in intestinal epithelial cells. Cell Death Dis 6:1655. https://doi.org/10.1038/cddis.2015.19 CrossRefPubMedPubMedCentral

33.

Song EJ, Lee SJ, Lim HS, Kim JS, Jang KK, Choi SH, Han HJ (2016) Vibrio vulnificus VvhA induces autophagy-related cell death through the lipid raft-dependent c-Src/NOX signaling pathway. Sci Rep 6:27080. https://doi.org/10.1038/srep27080 CrossRefPubMedPubMedCentral

34.

Lee NY, Lee HY, Lee KH, Han SH, Park SJ (2011) Vibrio vulnificus IlpA induces MAPK-mediated cytokine production via TLR1/2 activation in THP-1 cells, a human monocytic cell line. Mol Immunol 49(1–2):143–154. https://doi.org/10.1016/j.molimm.2011.08.001 CrossRefPubMed

35.

Kim WB, Lee BC, Choi SH (2012) Vibrio vulnificus AphB is involved in interleukin-8 production via an NF-kappaB-dependent pathway in human intestinal epithelial cells. Biochem Biophys Res Commun 417(4):1265–1270. https://doi.org/10.1016/j.bbrc.2011.12.122 CrossRefPubMed

36.

Liu M, Crosa JH (2012) The regulator HlyU, the repeat-in-toxin gene rtxA1, and their roles in the pathogenesis of Vibrio vulnificus infections. MicrobiologyOpen 1(4):502–513. https://doi.org/10.1002/mbo3.48 CrossRefPubMedPubMedCentral

37.

Baker-Austin C, Oliver JD (2016) Rapidly developing and fatal Vibrio vulnificus wound infection. IDCases 6:13. https://doi.org/10.1016/j.idcr.2016.07.014 CrossRefPubMedPubMedCentral

38.

Arici E, Evald A, Holmgaard DB, Quist L, Poulsen SD, Worm SW (2017) Amputation of an arm due to infection with Vibrio vulnificus after beach holiday. Ugeskr Laeger 179(48)

39.

Horseman MA, Surani S (2011) A comprehensive review of Vibrio vulnificus: an important cause of severe sepsis and skin and soft-tissue infection. Int J Infect Dis 15(3):e157–e166. https://doi.org/10.1016/j.ijid.2010.11.003 CrossRefPubMed

40.

Majere RA, Cortina S (2017) Necrotizing wound infection from a tilapia fish injury. CMAJ 189(14):E539–e541. https://doi.org/10.1503/cmaj.160663 CrossRefPubMedPubMedCentral

41.

Hendren N, Sukumar S, Glazer CS (2017) Vibrio vulnificus septic shofck due to a contaminated tattoo. BMJ Case Rep 2017. https://doi.org/10.1136/bcr-2017-22019

42.

Jones MK, Oliver JD (2009) Vibrio vulnificus: disease and pathogenesis. Infect Immun 77(5):1723–1733. https://doi.org/10.1128/iai.01046-08 CrossRefPubMedPubMedCentral

43.

Baker-Austin C, Oliver JD (2018) Vibrio vulnificus: new insights into a deadly opportunistic pathogen. Environ Microbiol 20(2):423–430. https://doi.org/10.1111/1462-2920.13955 CrossRefPubMed

44.

Elmahdi S, DaSilva LV, Parveen S (2016) Antibiotic resistance of Vibrio parahaemolyticus and Vibrio vulnificus in various countries: a review. Food Microbiol 57:128–134. https://doi.org/10.1016/j.fm.2016.02.008 CrossRefPubMed

45.

Serratore P, Zavatta E, Fiocchi E, Serafini E, Serraino A, Giacometti F, Bignami G (2017) Preliminary study on the antimicrobial susceptibility pattern related to the genotype of Vibrio vulnificus strains isolated in the north-western Adriatic Sea coastal area. Ital J Food Saf 6(4):6843. https://doi.org/10.4081/ijfs.2017.6843 CrossRefPubMedPubMedCentral

46.

Zanetti S, Spanu T, Deriu A, Romano L, Sechi LA, Fadda G (2001) In vitro susceptibility of Vibrio spp. isolated from the environment. Int J Antimicrob Agents 17(5):407–409CrossRef

47.

Shaw KS, Rosenberg Goldstein RE, He X, Jacobs JM, Crump BC, Sapkota AR (2014) Antimicrobial susceptibility of Vibrio vulnificus and Vibrio parahaemolyticus recovered from recreational and commercial areas of Chesapeake Bay and Maryland Coastal Bays. PLoS One 9(2):e89616. https://doi.org/10.1371/journal.pone.0089616 CrossRefPubMedPubMedCentral

48.

Trinh SA, Gavin HE, Satchell KJF (2017) Efficacy of ceftriaxone, cefepime, doxycycline, ciprofloxacin, and combination therapy for Vibrio vulnificus foodborne septicemia. Antimicrob Agents Chemother 61(12):e01106–17. https://doi.org/10.1128/aac.01106-17

49.

Tang HJ, Chang MC, Ko WC, Huang KY, Lee CL, Chuang YC (2002) In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus. Antimicrob Agents Chemother 46(11):3580–3584CrossRef

50.

Stevens DL, Bryant AE (2017) Necrotizing soft-tissue infections. N Engl J Med 377(23):2253–2265. https://doi.org/10.1056/NEJMra1600673 CrossRefPubMed

51.

Hong GL, Lu CJ, Lu ZQ, Li MF, Qiu QM, Liang H, Wu B (2012) Surgical treatment of 19 cases with vibrio necrotising fasciitis. Burns 38(2):290–295. https://doi.org/10.1016/j.burns.2011.04.013 CrossRefPubMed

52.

Osaka K, Komatsuzaki M, Takahashi H, Sakano S, Okabe N (2004) Vibrio vulnificus septicaemia in Japan: an estimated number of infections and physicians’ knowledge of the syndrome. Epidemiol Infect 132(5):993–996CrossRef

Titel: Epidemiology, pathogenetic mechanism, clinical characteristics, and treatment of Vibrio vulnificus infection: a case report and literature review
verfasst von: Fei Leng
Shilong Lin
Wei Wu
Jincheng Zhang
Jieqiong Song
Ming Zhong
Publikationsdatum: 19.07.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2019
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-019-03629-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2019

Genomic analysis of Staphylococcus capitis isolated from blood cultures in neonates at a neonatal intensive care unit in Sweden

Staphylococcus aureus nasal carriage among homeless population in Lisbon, Portugal

Antibiotic therapy for Enterococcus bacteraemia: warning for the antimicrobial stewardship team

Could aflatoxin B1 production by Aspergillus flavus affect the severity of keratitis: an experience in two tertiary health care centers, Egypt

In vitro activities of imipenem, vancomycin, and rifampicin against clinical Elizabethkingia species producing BlaB and GOB metallo-beta-lactamases